2023 World Conference on Lung Cancer (Posters)-EP12.01. Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib

EP12.01. Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib - PDF(Slides)

Back to course

Pdf Summary

This study aims to investigate the molecular markers of resistance in the first-line treatment of non-small cell lung cancer (NSCLC) with EGFR positive by aumolertinib, a third-generation EGFR tyrosine kinase inhibitor. The study is based on previous work and prospective data from patients at the Cancer Hospital Chinese Academy of Medical Sciences. The researchers aim to verify if certain molecular markers can predict the prognosis of NSCLC patients receiving aumolertinib as first-line therapy. These molecular markers include T790M/EGFR MAF ratio, FGFR1 amplification, MET amplification, PIK3CA mutation, PTEN mutation, BRAF mutation, and CDKN2A mutation.<br /><br />The study will include patients with locally advanced or metastatic NSCLC, with an ECOG performance status of 0-2. Patients will need to provide blood or tumor tissue samples before, after, and during disease progression, as well as complete clinical and pathological data. The researchers will analyze gene mutations, tumor mutation burden (TMB), and programmed death-ligand 1 (PD-L1) expression using next-generation sequencing (NGS) and PD-L1 immunohistochemistry (IHC). They will use Cox single factor and progression-free survival (PFS) to determine if the molecular markers are independent of TMB and PD-L1 for targeted therapy of lung cancer.<br /><br />The study is sponsored by the Chinese Society of Clinical Oncology Foundation and Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Its objectives are to explore molecular markers of drug resistance in lung cancer patients treated with aumolertinib and provide insights for guiding clinical treatment and new ideas for targeted therapy of lung cancer.

Asset Subtitle

Jian Chun Duan

Meta Tag

Speaker Jian Chun Duan

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

molecular markers

resistance

NSCLC

aumolertinib

prognosis

T790M/EGFR MAF ratio

FGFR1 amplification

MET amplification

PIK3CA mutation

targeted therapy